Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer`s Disease and Traumatic Brain Injury
Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced it has received a $3 million award from Advanced Technology International (ATI) to support the company’s Phase 1 study of PNT001 in hospitalized patients with acute traumatic brain injury. ATI is a nonprofit contractor of the U.S. Department of Defense (DOD) that identifies and sources solutions for the DOD from industry and academia. The funds will be awarded as milestone payments as the trial progresses.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlimab (BGB-A1217) in combination with its anti-PD-1 antibody tislelizumab, for the first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced that the first patient has been dosed in a Phase 1b multiple ascending dose study evaluating PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease, in patients with acute traumatic brain injury (TBI).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced that the first patient has been dosed in a Phase 1b multiple ascending dose study evaluating PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease, in patients with acute traumatic brain injury (TBI).